Abstract
In some parts of the world, medicinal cannabinoids have already been used to treat nausea and vomiting associated with chemotherapy and wasting in diseases such as AIDS and terminal cancer. However, over the last several years, currently used cannabinoids, such as dronabinol, as well as newly developed cannabis-based medicines such as Sativex® (narrow ratio combination of Δ9-tetrahydrocannabinol and cannabidiol), have been investigated for the treatment of spasticity, chronic pain, disruption of sleep and urinary dysfunction associated with multiple sclerosis and other neurological disorders. Although some clinical trials have yielded positive results, others have not and there has been controversy regarding the use of subjective rating scales to measure pain and spasticity. Adverse side effects have been generally mild and transient; however, researchers and clinicians are still concerned about the prospect of long-term adverse side effects. This review will summarise and critically evaluate the currently available clinical trial data.
Keywords: Cannabinoids, cannabis, multiple sclerosis, pain, spasticity
Current Drug Therapy
Title: Will Medicinal Cannabinoids Prove to be Useful Clinically?
Volume: 2 Issue: 2
Author(s): Paul F. Smith
Affiliation:
Keywords: Cannabinoids, cannabis, multiple sclerosis, pain, spasticity
Abstract: In some parts of the world, medicinal cannabinoids have already been used to treat nausea and vomiting associated with chemotherapy and wasting in diseases such as AIDS and terminal cancer. However, over the last several years, currently used cannabinoids, such as dronabinol, as well as newly developed cannabis-based medicines such as Sativex® (narrow ratio combination of Δ9-tetrahydrocannabinol and cannabidiol), have been investigated for the treatment of spasticity, chronic pain, disruption of sleep and urinary dysfunction associated with multiple sclerosis and other neurological disorders. Although some clinical trials have yielded positive results, others have not and there has been controversy regarding the use of subjective rating scales to measure pain and spasticity. Adverse side effects have been generally mild and transient; however, researchers and clinicians are still concerned about the prospect of long-term adverse side effects. This review will summarise and critically evaluate the currently available clinical trial data.
Export Options
About this article
Cite this article as:
Smith F. Paul, Will Medicinal Cannabinoids Prove to be Useful Clinically?, Current Drug Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157488507780619059
DOI https://dx.doi.org/10.2174/157488507780619059 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Surgical Treatment of Neonatal Mastitis by Periareolar Drainage
Current Pediatric Reviews Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction and Coronary Artery Spasm
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review
Current Pharmaceutical Design Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA The Role of Ultrasonography of Peripheral Entheses in the Diagnosis and Assessment of Spondyloarthropathies
Current Rheumatology Reviews Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Development of Nanocomponent Ointment Composition for the Treatment of Various Etiologies Wounds
Current Nanomedicine Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Anatomical and Functional Relationships Between Sensory Nerves and Mast Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology